Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The NEURESCUE device is the first intelligent balloon catheter for aortic balloon occlusion (ABO), an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment.
The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
The purpose of this study is to compare the clinical safety and performance of Advanced Cardiovascular Life Support (ACLS) versus ACLS in combination with Aortic Balloon Occlusion (ABO) using the NEURESCUE device in subjects with cardiac arrest.
Subjects will be randomized into two arms: ACLS treatment or ACLS + ABO treatment. Those in the ACLS treatment arm will receive standard of care treatment for cardiac arrest, while those in Arm 2 will receive ACLS in combination with ABO.
The NEURESCUE device is an aortic balloon catheter designed to temporarily occlude the aorta. During the treatment, the NEURESCUE Catheter will be placed in the descending aorta and be connected to the NEURESCUE Assistant. The NEURESCUE Assistant facilitates pressure-regulated inflation and deflation of the balloon.
Throughout the treatment, cardiac rhythm and return of spontaneous circulation (ROSC) will be monitored.
The subject will be monitored for a total of 4 visits, where a 90-days follow-up will account for the last visit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 (Control) | Active Comparator | Enrolled subjects randomized into Arm 1 will receive ACLS treatment. |
|
| Arm 2 (Intervention) | Experimental | Enrolled subjects randomized into Arm 2 will receive ACLS treatment combined with ABO. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Advanced Cardiac Life Support (ACLS) | Procedure | Standard of care Advanced Cardiac Life Support (ACLS) consists of cardiopulmonary resuscitation (CPR), airway management, ventilation and defibrillation. |
| Measure | Description | Time Frame |
|---|---|---|
| Resuscitation | Subject achieving shockable rhythm or ROSC | Measured from 10 minutes after randomization to 70 minutes after randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Epinephrine | Dosage of epinephrine administered during resuscitation | Measured from 10 minutes after randomization to 70 minutes after randomization |
| Procedures | Need for any invasive procedures, e.g. surgery, extracorporeal membrane oxygenation (ECMO) or percutaneous coronary intervention (PCI) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Michael Preusch, M.D. | Contact | +49 151 40044669 | Michael.Preusch@med.uni-heidelberg.de |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Charité - Universitätsklinikum Berlin | Recruiting | Berlin | 12203 | Germany |
Individual request
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006323 | Heart Arrest |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D022561 | Advanced Cardiac Life Support |
| ID | Term |
|---|---|
| D016887 | Cardiopulmonary Resuscitation |
| D012151 | Resuscitation |
| D004638 | Emergency Treatment |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Aortic balloon occlusion (ABO) | Device | Aortic balloon occlusion (ABO) is a technique that diverts blood flow towards the coronary and cerebral circulation. ABO is investigated as an adjunct to the treatment of cardiac arrest. In this study ABO is performed using the NEURESCUE Catheter, which is inserted through an introducer in the femoral artery, and thereby inserted into the aorta during uninterrupted Advanced Cardiac Life Support (ACLS). The balloon is then temporarily inflated as an adjunct to the treatment of cardiac arrest. |
|
| Measured from 10 minutes after randomization to 90 days post cardiac arrest |
| (S)A(D)E | All Anticipated (S)AEs/(S)ADEs and Unanticipated (S)AEs/(S)ADEs | Measured from randomization to 90 days post cardiac arrest |
| CPC score | Cerebral Performance Category (CPC) is a five-point scale used to categorize the neurological outcome after cardiac arrest | Measured at dischage or at 7 days post cardiac arrest, and 90 days post cardiac arrest |
| EQ-5D | EQ-5D is a standardized measure of quality of life | Measured 90 days post cardiac arrest |
| Survival | Survival at discharge or 7 day post cardiac arrest (whichever comes first), and survival at 90 days post cardiac arrest | Measured at dischage or at 7 days post cardiac arrest, and 90 days post cardiac arrest |
| University Hospital Heidelberg | Recruiting | Heidelberg | 69120 | Germany |
|
| D008020 |
| Life Support Care |
| D005791 | Patient Care |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |